aTYR PHARMA INC
For the period ended Jun 30, 2025. Filed Aug 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 7, 2025
ATYR$7.58+19.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
During the period covered by this report, our Chief Financial Officer and General Counsel adopted a contract, instructions or written plans for the sale of our securities as noted below:
| Trading Arrangement · Total Shares Authorized · Expiration | |||||
|---|---|---|---|---|---|
| Name and Title · Action · Date · Rule 10b5-1* · Non-Rule 10b5-1** · to be Sold*** · Date | |||||
| Jill M. Broadfoot | Adoption | 6/16/2025 | X | 252,514 | 6/16/2026 |
| Chief Financial Officer | |||||
| Nancy E. Denyes | Adoption | 6/13/2025 | X | 100,000 | 6/13/2026 |
| General Counsel | |||||
| * | Intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. |
|---|---|
| ** | "Non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K under the Exchange Act. |
| *** | Represents the maximum number of shares that may be sold pursuant to the 10b5-1 trading arrangement. The number of shares sold is dependent on the satisfaction of certain conditions as set forth in the written plan and the satisfaction of applicable vesting conditions of equity awards. These shares would be sold through option exercises pursuant to employee stock option grants. |
Item 6. Exhibits
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.